Liontrust Investment Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Liontrust Investment Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-54,442	Closed	-$5.6M	–	227
2023 Q2	$5.6M	Buy	+54,442	New	+$5.74M	0.08%	127
2022 Q3	–	Sell	-191,242	Closed	-$15.3M	–	273
2022 Q2	$15.3M	Buy	191,242 +6,000	+3%	+$568K	0.21%	63
2022 Q1	$19.5M	Hold	185,242	–	–	0.25%	49
2021 Q4	$20M	Sell	185,242 -55,000	-23%	-$6M	0.24%	51
2021 Q3	$26.3M	Buy	+240,242	New	+$24.9M	0.36%	43
2020 Q4	$18.9M	Buy	+258,642	New	+$19.2M	0.38%	46

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Liontrust Investment Partners's HZNP Position: Q3 2023 in Review

Liontrust Investment Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 54,442 shares — an estimated $5.6M sold.

Liontrust Investment Partners first reported a position in HZNP in Q4 2020 and held it in 6 quarters. The position peaked at $26.3M in Q3 2021. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

Liontrust Investment Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Liontrust Investment Partners sold 54,442 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $5.6M.
Liontrust Investment Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 6 quarters.
Liontrust Investment Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $26.3M in Q3 2021.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Liontrust Investment Partners's 13F filing for Q3 2023, filed 9 Nov 2023.